Evaluation of Xuefu Zhuyu Oral Solution as an Add-on Therapy for Stable Angina: Results from a Randomized Controlled Trial
-
By
-
Wencong Cao
-
Shaojun Liao
-
Li Zhou
-
Geng Li
-
Junwen Jiang
-
Weihui Lv
-
Bo Dong
-
Li Liu
-
Jie Zhang
-
Yanchun Wang
-
Wenwei Ouyang
-
Yi Du
-
Zehuai Wen
-
April 29, 2026
-
Clinical Scorecard: Evaluation of Xuefu Zhuyu Oral Solution as an Add-on Therapy for Stable Angina: Results from a Randomized Controlled Trial
At a Glance
| Category | Detail |
|---|
| Condition | Stable angina (SA) due to myocardial ischemia |
| Key Mechanisms | Multi-target effects including inhibition of platelet aggregation, anti-atherosclerosis, lipid reduction, inflammation reduction, endothelial repair, and plaque stabilization |
| Target Population | Patients aged 30–75 years with stable angina and Qi stagnation and Blood stasis (QBS) pattern per Chinese Medicine diagnosis |
| Care Setting | Multicenter hospital outpatient settings in China |
Key Highlights
- XZOL adjunctive therapy significantly reduced angina pain intensity measured by VAS at 12 and 24 weeks compared to placebo
- XZOL group had significantly lower use of rescue nitroglycerin at both 12 and 24 weeks
- XZOL demonstrated a favorable safety profile with adverse events comparable to placebo
Guideline-Based Recommendations
Diagnosis
- Confirm stable angina diagnosis per 2018 Chinese Society of Cardiology and 2002 AHA/ACC guidelines
- Assess Canadian Cardiovascular Society (CCS) angina severity grade I–III
- Use validated Chinese Medicine diagnostic instrument for Qi stagnation and Blood stasis (QBS) pattern
Management
- Use Xuefu Zhuyu oral liquid (XZOL) as adjunctive therapy to standard antianginal treatment for 12 weeks
- Continue standard guideline-directed medical therapy alongside XZOL
- Monitor and adjust rescue nitroglycerin use as needed
Monitoring & Follow-up
- Assess angina pain intensity using a 10-cm visual analog scale (VAS) at baseline, 12 weeks, and 24 weeks
- Monitor rescue nitroglycerin consumption during treatment and follow-up
- Observe for adverse events and compare incidence to baseline and placebo
Risks
- XZOL was well tolerated with adverse events comparable to placebo; no significant safety concerns identified
Patient & Prescribing Data
Patients with stable angina, CCS grade I–III, and QBS pattern aged 30–75 years
XZOL adjunctive therapy reduces angina pain and rescue medication use with good safety, supporting its use as complementary treatment in stable angina
Clinical Best Practices
- Ensure rigorous diagnosis of stable angina and QBS pattern before initiating XZOL
- Use XZOL as an add-on to, not a replacement for, standard antianginal therapies
- Monitor patient symptoms and rescue medication use regularly to assess treatment efficacy
- Educate patients on the complementary role of XZOL and maintain vigilance for any adverse events
References
